Stockscreener 앱 받기
5.22
0.77%
0.04
시간 외 거래:
5.30
0.08
+1.53%
전일 마감가:
$5.18
열려 있는:
$5.18
하루 거래량:
856.63K
Relative Volume:
0.86
시가총액:
$313.91M
수익:
$217.78M
순이익/손실:
$-239.55M
주가수익비율:
-1.2891
EPS:
-4.0492
순현금흐름:
$-127.30M
1주 성능:
-1.88%
1개월 성능:
-13.14%
6개월 성능:
-34.91%
1년 성능:
+10.13%
1일 변동 폭
$5.18
$5.33
1주일 범위
$5.12
$5.53
52주 변동 폭
$4.14
$9.94
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
명칭
Vanda Pharmaceuticals Inc
전화
202-734-3400
주소
2200 PENNSYLVANIA AVE NW, WASHINGTON
Compare VNDA vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
5.22 | 311.50M | 217.78M | -239.55M | -127.30M | -4.0492 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-05 | 개시 | Truist | Buy |
| 2025-11-05 | 개시 | B. Riley Securities | Buy |
| 2024-10-31 | 개시 | H.C. Wainwright | Buy |
| 2024-07-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-02-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-05-12 | 개시 | BofA Securities | Buy |
| 2021-01-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-10-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-06-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-03-16 | 다운그레이드 | Oppenheimer | Perform → Underperform |
| 2020-03-12 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-11-07 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-08-01 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-07-25 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-12-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2018-12-04 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2018-12-04 | 재확인 | Jefferies | Buy |
| 2018-11-08 | 재개 | Jefferies | Buy |
| 2018-09-21 | 재개 | Oppenheimer | Outperform |
| 2018-05-23 | 개시 | Citigroup | Buy |
| 2018-01-19 | 개시 | Seaport Global Securities | Buy |
| 2017-09-14 | 재확인 | Piper Jaffray | Overweight |
| 2017-06-27 | 재개 | Piper Jaffray | Overweight |
| 2017-05-26 | 개시 | H.C. Wainwright | Buy |
| 2017-04-12 | 개시 | Oppenheimer | Outperform |
| 2016-11-09 | 개시 | Aegis Capital | Buy |
| 2016-10-06 | 재개 | Jefferies | Buy |
모두보기
Vanda Pharmaceuticals Inc 주식(VNDA)의 최신 뉴스
Vanda Pharmaceuticals Inc (VNDA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Vanda Pharmaceuticals Inc (VNDA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
VNDA Stock Rises After Hours On Commercial Launch Of Motion Sickness Drug - Stocktwits
Vanda Pharmaceuticals Inc (VNDA) Valuation: PE, PB & Fair Value Analysis - TradingKey
VNDA|Vanda Pharmaceuticals Inc|Price:5.280|Chg%:+0.100 - TradingKey
Vanda Pharma Stock Rises Pre-Market After FDA Accepts Imsidolimab Filing For Rare Skin Disorder - Stocktwits
VNDA|Vanda Pharmaceuticals Inc|Price:5.280|Chg%:-0.080 - TradingKey
Vanda's NDA Rejection Challenge Can't Be Heard At DC Court - Law360
ETFs Investing in Vanda Pharmaceuticals Inc. Stocks - TradingView
Licensable picture: Vanda Pharmaceuticals Athens OpenDay 5 - reutersconnect.com
VNDA Stock Soars 40% Overnight After Bysanti Approval: What’s The Next Catalyst And How Much Upside Remains? - Stocktwits
Vanda PharmaceuticalsRisks Rising, Rewards DwindlingWhy I'm Downgrading To Hold - Seeking Alpha
Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular PsoriasisA Milestone Recognition of GPP as a Distinct Rare Disease in Europe - Sahm
Vanda Pharmaceuticals Announces EMA Positive Opinion For Orphan Drug Designation Of Imsidolimab For GPP - TradingView
Vanda Pharmaceuticals (VNDA) Receives Orphan Drug Designation fo - GuruFocus
EMA Panel Recommends First EU Orphan Designation for Rare Skin Disease - Stock Titan
Vanda shifts Nereus marketing into high gear with Schumacher IndyCar sponsorship - Fierce Pharma
Insider Sellers Might Regret Selling Vanda Pharmaceuticals Shares at a Lower Price Than Current Market Value - simplywall.st
NEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment - Sahm
Vanda Pharmaceuticals Athens OpenDay 4 - reutersconnect.com
NEREUStm Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment - Lelezard
NEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrati - GuruFocus
Vanda Pharma's new motion sickness drug NEREUS™... - Pluang
IndyCar News: Vanda Pharmaceuticals Sponsor Schumacher for Four Races - AutoRacing1.com
Has Vanda Pharmaceuticals Finally Found Its Game-Changer with Bysanti - Kavout | AI
Vanda Pharmaceuticals to be Primary Sponsor of Mick Schumacher’s INDYCAR Entry for Four Races Beginning in Nashville This Weekend - Catchfence
Vanda Pharmaceuticals To Be Primary Sponsor Of Schumacher’s INDYCAR Entry For Four Races; Schumacher to Pilot the No. 47 NEREUS™ Honda at events in Nashville, Portland, Washington D.C. and Monterey - Rahal Letterman Lanigan
47 years since the last new motion-sickness treatment, NEREUS will sponsor IndyCar - Stock Titan
Judge Says Vanda-FDA Appointments Fight Likely Ripe - Law360
Vanda Fights to Sway Court to Keep Suit Over FDA’s Drug Reviews - Bloomberg Law News
Daniel Patrick Mcguire Net Worth (2026) - GuruFocus
Vanda Pharmaceuticals (VNDA) Slides 3.85% as Stock Tests Key Support at $5.7TICK Divergence - DonanımHaber
Vanda Now Looks To Public Hearing For Hetlioz In Jet Lag Disorder After Multiple FDA Rejections - Stocktwits
Vanda Pharmaceuticals to join B. Riley Summit f... - Pluang
Vanda Pharmaceuticals plans fireside chat at Boston investor summit - Stock Titan
Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit - PR Newswire
H.C. Wainwright reiterates Vanda Pharmaceuticals stock rating on FDA designation By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Vanda Pharmaceuticals stock rating on FDA designation - Investing.com India
Vanda’s antisense therapy wins FDA rare pediatric disease designation for CMT2S - AllSci
Why Did Vanda Pharmaceuticals Stock Slide 7% Pre-Market Today? - Stocktwits
Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Desig - GuruFocus
VNDA Stock Gains After-Hours As FDA Grants Rare Pediatric Disease Designation For Experimental Therapy - Stocktwits
Vanda Pharmaceuticals (VNDA) Receives FDA Rare Pediatric Disease Designation - GuruFocus
Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S - Quantisnow
Vanda Pharmaceuticals updates investors on business outlook as shares trade in the U.S. market - ad-hoc-news.de
VNDA Stock Rallies After-Hours As FDA Approves Schizophrenia, Bipolar Disorder Drug - Stocktwits
VNDAVanda Pharmaceuticals Inc Volatility & Greeks - Finviz
McDermott Represents Vanda Pharmaceuticals Inc. on Acquisition of PONVORY® - McDermott Will & Schulte
Here’s Why H.C. Wainwright Remains a Buy on Vanda Pharmaceuticals (VNDA) - Yahoo Finance
Vanda Pharmaceuticals | 3: Initial statement of beneficial ownership of securities- McGuire Daniel Patrick - Moomoo
Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) dropped from Russell 2000 Defensive Index - marketscreener.com
Vanda Pharmaceuticals Inc (VNDA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.97%
0.83%
자본화:
|
볼륨(24시간):